Trial Profile

Phase I trial of mesencephalic astrocyte-derived neurotrophic factor (MANF) in patients with Parkinson's disease.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 19 May 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesencephalic astrocyte-derived neurotrophic factor (Primary)
Indications Parkinson's disease
Focus Adverse reactions

Most Recent Events

14 May 2015 This trial in Parkinson's disease appears to have been withdrawn prior to enrolment, as Amarantus BioScience Holdings is targeting retinitis pigmentosa for first-in-man studies of mesencephalic astrocyte-derived growth factor, as reported in a media release.
09 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com